Aberdeen Group plc and its subsidiary abrdn Inc. filed an amended beneficial ownership statement with the SEC on October 29, 2026, disclosing that they no longer hold any shares of Corbus Pharmaceuticals Holdings, Inc. common stock as of September 16, 2026.

Key Highlights

  • Zero beneficial ownership: Both Aberdeen Group plc and abrdn Inc. report 0 shares beneficially owned in Corbus Pharmaceuticals Holdings, Inc. common stock (CUSIP 21833P301).
  • Triggering event date: The date of the event requiring this filing was September 16, 2026, according to the document.
  • All voting and dispositive power eliminated: Each reporting person discloses 0 shares for sole voting power, shared voting power, sole dispositive power, and shared dispositive power.
  • Percent of class: The filing states 0% of the outstanding class is held by either reporting person.
  • Filing type: This is Amendment No. 1 to a prior filing, signed by Romiza Chaudhry, Major Shareholding Reporting Analyst, on October 5, 2026 on behalf of both entities.
  • Ownership threshold: Item 5 of the filing characterizes the position as "Ownership of 5 percent or less of a class."

Aberdeen Group and abrdn Inc. Confirm Full Exit from Corbus Pharmaceuticals

According to the filing, Aberdeen Group plc, organized in the United Kingdom and headquartered at 1 George Street, Edinburgh, serves as the parent holding company in this disclosure. Its subsidiary abrdn Inc., a United States entity headquartered at 1900 Market Street Suite 200, Philadelphia, Pennsylvania, is classified as both a corporation and an investment adviser. The filing identifies abrdn Holdings Limited as an intermediate holding company sitting between Aberdeen Group plc and abrdn Inc.

The exhibit attached to the filing states directly that "abrdn Inc. no longer beneficially owns on behalf of our underlying clients any of the outstanding shares of the security class being reported on this Schedule 13G." This language indicates that the position, which had previously been held on behalf of underlying investment clients, has been fully disposed of. Corbus Pharmaceuticals Holdings, Inc., the issuer, is a pharmaceutical company whose common stock carries a par value of $0.0001 per share and is listed on NASDAQ:CRBP, with principal executive offices located at 500 River Ridge Drive, Norwood, Massachusetts 02062.

The amendment was signed by Romiza Chaudhry in her capacity as Major Shareholding Reporting Analyst, certifying on behalf of both Aberdeen Group plc and abrdn Inc. that the securities were held in the ordinary course of business and not for the purpose of influencing control of the issuer, as stated in Item 10 of the filing.

What Was Disclosed

Aberdeen Group plc and abrdn Inc. filed an amendment disclosing that, as of September 16, 2026, neither entity holds any beneficial ownership in Corbus Pharmaceuticals Holdings, Inc. common stock, representing 0% of the outstanding class.